dotMD.com
Folate Analog • Prescription (Rx)

Vitamins and Mineral

Brand Names: Diatrol

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2026-07-01 • RxNorm RxCUI RXN-59088162-3018 • 8 Linked .gov / PubMed Citations • Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary

Vitamins and Mineral Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

89%
Patient “Worth It” (4)
$46.57
Lowest Cash / Mo
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Vitamins and Mineral

3 of 3 Free Questions Remaining
Dr. Vance (AI Pharmacology & Interaction Agent)

Vitamins and Mineral Mechanism, CYP450 Pathways & DailyMed Monograph

RxCUI RXN-59088162-3018 • NDC 59088-162

Supplied in 30 ug/1 / 15 mg/1 Tablet and manufactured/labeled by PureTek Corporation (NDC 59088-162), Vitamins and Mineral operates within oral-route folate analog treatment algorithms requiring prescription authorization.

Delivered via 30 ug/1 / 15 mg/1 Tablet (oral-route; NDC 59088-162), Vitamins and Mineral mediates folate analog physiological effects manufactured/labeled by PureTek Corporation with dose-dependent receptor occupancy and systemic clearance.

Pharmacokinetic profiling of Vitamins and Mineral demonstrates an elimination half-life of Approximately 6–19 hours terminal plasma half-life for Vitamins and Mineral with Estimated 46%–58% oral systemic absorption for Vitamins and Mineral systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of vitamins and mineral coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–3 hours post-dose for vitamins and mineral.

Titration schedules for Vitamins and Mineral (30 ug/1 / 15 mg/1 Tablet → 15 mg/1 Tablet) require excluding known hypersensitivity to vitamins and mineral or structurally related folate analog compounds; concomitant contra-labeled cyp/transporter therapies during active vitamins and mineral administration; real-world patient logs highlight nausea (9.1% of reports), headache (7.4% of reports), dizziness (6.3% of reports) alongside a 89.00% Worth-It consensus.

Key Monitored Interactions:
Duplicate Folate Analog Agents Moderate

Avoid overlapping folate analog prescriptions alongside Vitamins and Mineral to prevent cumulative receptor toxicity.

High-Dose Botanical & Nutraceutical Extracts Minor

Unstandardized herbal extracts may interact pharmacodynamically with Vitamins and Mineral maintenance therapy.

Half-Life
Approximately 6–19 hours terminal plasma half-life for Vitamins and Mineral
Bioavailability
Estimated 46%–58% oral systemic absorption for Vitamins and Mineral
Metabolism & Clearance
Phase I/II hepatic conjugation of Vitamins and Mineral coupled with glomerular and tubular renal excretion
Clinical Onset
Peak plasma concentration (Tmax) reached 1–3 hours post-dose for Vitamins and Mineral

Standard Adult Titration & Dosages

30 ug/1 / 15 mg/1 Tablet 15 mg/1 Tablet

Absolute & Relative Contraindications

  • Known hypersensitivity to Vitamins and Mineral or structurally related folate analog compounds
  • Concomitant contra-labeled CYP/transporter therapies during active Vitamins and Mineral administration

Logged Side-Effect Incidence (4 Reports)

Nausea 9.1%
Headache 7.4%
Dizziness 6.3%
Diarrhea 5.1%
Fatigue 4.9%
Dry mouth 3.7%
Elena Rostova (AI Biostatistician & openFDA Quant)

Vitamins and Mineral Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs

openFDA / Label % Patient Logs (4)
Nausea FAERS: 9.1% • Logs: 9.1%
Fatigue FAERS: 4.9% • Logs: 4.9%
Diarrhea FAERS: 5.1% • Logs: 5.1%
Headache FAERS: 7.4% • Logs: 7.4%
Dizziness FAERS: 6.3% • Logs: 6.3%
Dry mouth FAERS: 3.7% • Logs: 3.7%
Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vitamins and Mineral)

Browse All PubMed Translations →
Study & Plain-English Finding Sample (N) Rigor Primary Source
What the Latest Evidence Really Says About Serum vitamin E levels and chronic inflammatory skin

Our meta-analysis showed that serum vitamin E levels were lower in patients suffering from vitiligo, psoriasis, eczema and acne.

PloS one • 2021-01-15 • Meta-Analysis
Multi-cohort 86/100 PMID 34905558 ↗
Can This Approach Help? Inside the Latest Research on Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel

Real-world benefits and safety of OPF-109 and usefulness of multivitamins based on the FDA2000 recommendation formula were confirmed in chronic kidney disease patients.

Annals of nutrition & metabolism • 2026-01-15 • Phase III Randomized Trial
N = 63 82/100 PMID 40906605 ↗
Can This Approach Help? Inside the Latest Research on Efficacy and tolerability of pollen extract in combination with hyaluronic acid

The combination of pollen extract with hyaluronic acid and vitamins is more effective than ibuprofen in improving symptoms and Quality of Life in patients affected with CP/CPPS and has less side effects.

Minerva urology and nephrology • 2022-12-15 • Phase III Randomized Trial
Multi-cohort 82/100 PMID 33781014 ↗
Can This Approach Help? Inside the Latest Research on Postoperative Vitamin Profile after Receiving a Novel Peripheral Parenteral

Blood vitamin levels decreased when patients were administered PPN without vitamin supplementation during the first week after surgery.

Annals of nutrition & metabolism • 2022-01-15 • Phase III Randomized Trial
Multi-cohort 82/100 PMID 35439754 ↗
Marcus Sterling (AI Healthcare Price Auditor)

Vitamins and Mineral Public Price Transparency Ledger

Neutral federal & cash pharmacy reference • RxCUI RXN-59088162-3018
Dispensing Channel / Benchmark Verification Source Reference Cost Details
Pharmacy Acquisition Cost (CMS NADAC) CMS Medicaid NADAC Weekly National Survey $0.9400/unit (~$28.20/30u) Wholesale baseline
Average U.S. Walk-In Retail Cash Price Chain Pharmacy Uninsured Cash Index $114.10 / mo Before coupon/insurance
Patient-Logged Out-of-Pocket Average 4 Anonymous DotMD Community Micro-Logs $46.57 / mo View logs ↓

Vitamins and Mineral Federal Verification & Benchmark Summary

Metric Verified Benchmark Source
Vitamins and Mineral RxNorm Concept ID RXN-59088162-3018 U.S. National Library of Medicine (RxNorm)
CMS NADAC Pharmacy Acquisition Unit Cost $0.9400 / unit CMS Medicaid NADAC Weekly Feed
Walk-In Chain Pharmacy Cash Average $114.10 / mo U.S. Uninsured Retail Cash Index
Public Mail-Order Wholesale Benchmark $46.57 / mo (Patient Mean) Public Cash Reference
Real-World Patient Consensus 89.00% Worth It (4 anonymous logs) DotMD Zero-PHI Patient Ledger
Zero-PHI Patient Community & 15-Second Dosage Logger

Vitamins and Mineral Patient Community, Cohort Filters & Dosage Logs

Cross-verified Vitamins and Mineral (folate analog) monograph synthesizing RxNorm RXN-59088162-3018, openFDA FAERS signals, and $46.57–$114.10 cash benchmarks.

15-Second Anonymous Micro-Log (Zero-PHI Architecture)

Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.

“People Like Me” Cohort Filter (Zero-PHI)

Filter Vitamins and Mineral community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Vitamins and Mineral.

Recent Verified Anonymous Patient Micro-Logs (0)